1 1460 147 DISORDERS OF CONSCIOUSNESS AND PHARMACEUTICALS THAT ACT ON OXYGEN BASED AMINO ACID AND MONOAMINE NEUROTRANSMITTER PATHWAYS OF THE BRAIN. OXYGEN BASED NEUROTRANSMITTERS IN THE SYNAPSES OF THE BRAIN ARE PROPOSED TO PLAY AN IMPORTANT ROLE IN THE GENERATION OF CONSCIOUSNESS. THEY INCLUDE THE AMINO ACIDS GLUTAMATE AND GABA WHICH USE KREBS CYCLE PRECURSORS FOR THEIR SYNTHESIS, AND THE MONOAMINES DOPAMINE, NORADRENALIN, ADRENALIN AND SEROTONIN, WHICH ARE DERIVED FROM TYROSINE AND TRYPTOPHAN. DURING ISCHEMIA AFTER AN ACUTE BRAIN INJURY, A GABA SURGE OFTEN INITIATES BRAIN SUPPRESSION. IT HAS BEEN PROPOSED THAT WITH CHRONIC ISCHEMIA, A SECONDARY, POSSIBLY EPIGENETIC RESPONSE OCCURS WHEN NEUROTRANSMITTERS DEPLETE, A GLUCOSE AND OXYGEN SAVING MECHANISM TERMED NEURODORMANCY THAT MAY INVOKE ALTERNATIVE LONG TERM LOW ENERGY METABOLIC PATHWAYS IN THE BRAIN, ENCOUNTERED IN DISORDERS OF CONSCIOUSNESS. SOME MEDICATIONS CAN REVERSE DISORDERS OF CONSCIOUSNESS IN SOME PATIENTS. VIRTUALLY ALL OF THEM ACT ON NEUROTRANSMITTER SYSTEMS THAT USE OXYGEN AS A BUILDING BLOCK OR AS AN ENERGY SOURCE WITHIN THE BRAIN. PHARMACEUTICALS THAT ACT IN THE OXYGEN BASED AMINO ACID SYSTEMS OF THE BRAIN INCLUDE THE GABAERGIC MEDICATIONS ZOLPIDEM AND BACLOFEN, WHILE THOSE THAT ACT IN THE MONOAMINE AXES INCLUDE THE DOPAMINERGIC MEDICATIONS L DOPA, AMANTADINE, BROMOCRIPTINE, APOMORPHINE AND METHYLPHENIDATE, AND THE NORADRENERGIC AND SEROTONERGIC MEDICATIONS DESIPRAMINE, AMITRIPTYLINE, PROTRIPTYLINE AND FLUOXETINE. ANOTHER GROUP ARE THE CHOLINESTERASE INHIBITORS, RESPONSIBLE FOR INCREASING ACETYLCHOLINE, WHICH IS SYNTHESIZED FROM THE KREBS CYCLE INITIATOR, ACETYL COA. IT APPEARS THAT PHARMACEUTICALS THAT ARE ACTIVE IN THE OXYGEN BASED NEUROTRANSMITTER PATHWAYS OF THE BRAIN ARE SUCCESSFUL TO AROUSE TO CONSCIOUSNESS PATIENTS THAT SUFFER FROM ITS DISORDERS. RESEARCH NEEDS TO BE SUPPORTED AS FOUNDATION TO UNDERSTAND THE BIOCHEMICAL MECHANISMS THAT ARE INVOLVED IN CONSCIOUSNESS DISORDERS AND TO EXPLORE FURTHER THE PHARMACOLOGICAL TREATMENT POSSIBILITIES FOR THESE DEVASTATING NEUROLOGICAL CONDITIONS. 2014 2 3346 29 HISTONE DEACETYLASES MEDIATE GABA(A) RECEPTOR EXPRESSION, PHYSIOLOGY, AND BEHAVIORAL MALADAPTATIONS IN RAT MODELS OF ALCOHOL DEPENDENCE. ALCOHOL USE DISORDERS ARE CHRONIC DEBILITATING DISEASES CHARACTERIZED BY SEVERE WITHDRAWAL SYMPTOMS THAT CONTRIBUTE TO MORBIDITY AND RELAPSE. GABA(A) RECEPTOR (GABA(A)R) ADAPTATIONS HAVE LONG BEEN IMPLICATED IN THE CHRONIC EFFECTS OF ALCOHOL AND CONTRIBUTE TO MANY WITHDRAWAL SYMPTOMS ASSOCIATED WITH ALCOHOL DEPENDENCE. IN RODENTS, GABA(A)R HYPOFUNCTION RESULTS FROM DECREASES IN GABRA1 EXPRESSION, ALTHOUGH THE UNDERLYING MECHANISM CONTROLLING GABRA1 EXPRESSION AFTER CHRONIC ETHANOL EXPOSURE IS STILL UNKNOWN. WE FOUND THAT CHRONIC ETHANOL EXPOSURE USING EITHER ETHANOL GAVAGE OR TWO-BOTTLE CHOICE VOLUNTARY ACCESS PARADIGMS DECREASED GABRA1 EXPRESSION AND INCREASED HDAC2 AND HDAC3 EXPRESSION. ADMINISTRATION OF THE HDAC INHIBITOR TRICHOSTATIN A (TSA) AFTER CHRONIC ETHANOL EXPOSURE PREVENTS THE DECREASE IN GABRA1 EXPRESSION AND FUNCTION AS WELL AS THE INCREASE IN HDAC2 AND HDAC3 EXPRESSION IN BOTH THE CORTEX AND THE MEDIAL PREFRONTAL CORTEX (MPFC). CHRONIC ETHANOL EXPOSURE AND WITHDRAWAL, BUT NOT ACUTE ETHANOL EXPOSURE OR ACUTE WITHDRAWAL, CAUSE A SELECTIVE UPREGULATION OF HDAC2 AND HDAC3 ASSOCIATED WITH THE GABRA1 PROMOTER THAT ACCOMPANIES A DECREASE IN H3 ACETYLATION OF THE GABRA1 PROMOTER AND THE REDUCTION IN GABA(A)R ALPHA1 SUBUNIT EXPRESSION. TSA ADMINISTRATION PREVENTED EACH OF THESE MOLECULAR EVENTS AS WELL AS BEHAVIORAL MANIFESTATIONS OF ETHANOL DEPENDENCE, INCLUDING TOLERANCE TO ZOLPIDEM-INDUCED LOSS OF RIGHTING REFLEX, REDUCED OPEN-ARM TIME IN THE ELEVATED PLUS MAZE, REDUCED CENTER-TIME AND LOCOMOTOR ACTIVITY IN THE OPEN-FIELD ASSAY, AND TSA REDUCED VOLUNTARY ETHANOL CONSUMPTION. THE RESULTS SHOW HOW CHRONIC ETHANOL EXPOSURE REGULATES THE HIGHLY PROMINENT GABA(A)R ALPHA1 SUBUNIT BY AN EPIGENETIC MECHANISM THAT REPRESENTS A POTENTIAL TREATMENT MODALITY FOR ALCOHOL DEPENDENCE. 2018 3 6352 31 THE ROLE OF GABA(A) RECEPTORS IN THE DEVELOPMENT OF ALCOHOLISM. ALCOHOLISM IS A COMMON, HERITABLE, CHRONIC RELAPSING DISORDER. GABA(A) RECEPTORS UNDERGO ALLOSTERIC MODULATION BY ETHANOL, ANESTHETICS, BENZODIAZEPINES AND NEUROSTEROIDS AND HAVE BEEN IMPLICATED IN THE ACUTE AS WELL AS THE CHRONIC EFFECTS OF ETHANOL INCLUDING TOLERANCE, DEPENDENCE AND WITHDRAWAL. MEDICATIONS TARGETING GABA(A) RECEPTORS AMELIORATE THE SYMPTOMS OF ACUTE WITHDRAWAL. ETHANOL INDUCES PLASTICITY IN GABA(A) RECEPTORS: TOLERANCE IS ASSOCIATED WITH GENERALLY DECREASED GABA(A) RECEPTOR ACTIVATION AND DIFFERENTIALLY ALTERED SUBUNIT EXPRESSION. THE DOPAMINE (DA) MESOLIMBIC REWARD PATHWAY ORIGINATING IN THE VENTRAL TEGMENTAL AREA (VTA), AND INTERACTING STRESS CIRCUITRY PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF ADDICTION. VTA GABAERGIC INTERNEURONS ARE THE PRIMARY INHIBITORY REGULATORS OF DA NEURONS AND A SUBSET OF VTA GABA(A) RECEPTORS MAY BE IMPLICATED IN THE SWITCH FROM HEAVY DRINKING TO DEPENDENCE. GABA(A) RECEPTORS MODULATE ANXIETY AND RESPONSE TO STRESS; IMPORTANT ELEMENTS OF SUSTAINED DRINKING AND RELAPSE. THE GABA(A) RECEPTOR SUBUNIT GENES CLUSTERED ON CHROMOSOME 4 ARE HIGHLY EXPRESSED IN THE REWARD PATHWAY. SEVERAL RECENT STUDIES HAVE PROVIDED STRONG EVIDENCE THAT ONE OF THESE GENES, GABRA2, IS IMPLICATED IN ALCOHOLISM IN HUMANS. THE INFLUENCE OF THE INTERACTION BETWEEN ETHANOL AND GABA(A) RECEPTORS IN THE REWARD PATHWAY ON THE DEVELOPMENT OF ALCOHOLISM TOGETHER WITH GENETIC AND EPIGENETIC VULNERABILITIES WILL BE EXPLORED IN THIS REVIEW. 2008 4 3331 30 HISTONE DEACETYLASE INHIBITOR SUBERANILOHYDROXAMIC ACID TREATMENT REVERSES HYPOSENSITIVITY TO GAMMA-AMINOBUTYRIC ACID IN THE VENTRAL TEGMENTAL AREA DURING ETHANOL WITHDRAWAL. BACKGROUND: THE VENTRAL TEGMENTAL AREA (VTA) IS IMPORTANT FOR ALCOHOL-RELATED REWARD AND REINFORCEMENT. MOUSE VTA NEURONS ARE HYPOSENSITIVE TO GAMMA-AMINOBUTYRIC ACID (GABA) DURING ETHANOL (ETOH) WITHDRAWAL, AND GABA RESPONSIVENESS IS NORMALIZED BY IN VITRO TREATMENT WITH HISTONE DEACETYLASE INHIBITORS (HDACI). THE PRESENT STUDY EXAMINED THE EFFECT OF A SYSTEMICALLY ADMINISTERED HDACI, SUBERANILOHYDROXAMIC ACID (SAHA) ON GABA SENSITIVITY, AND RELATED MOLECULAR CHANGES IN VTA NEURONS DURING WITHDRAWAL AFTER CHRONIC ETOH INTAKE IN RATS. METHODS: SPRAGUE DAWLEY MALE ADULT RATS WERE FED WITH LIEBER-DECARLI DIET (9% ETOH OR CONTROL DIET) FOR 16 DAYS. EXPERIMENTAL GROUPS INCLUDED CONTROL DIET-FED AND ETOH DIET-FED (0- OR 24-HOUR WITHDRAWAL) RATS TREATED WITH EITHER SAHA OR VEHICLE INJECTION. SINGLE-UNIT RECORDINGS WERE USED TO MEASURE THE RESPONSE OF VTA NEURONS TO GABA. IMMUNOHISTOCHEMISTRY WAS PERFORMED TO EXAMINE LEVELS OF HDAC2, ACETYLATED HISTONE H3 LYSINE 9 (ACH3K9), AND GABA(A) RECEPTOR ALPHA1 AND ALPHA5 SUBUNITS IN THE VTA; QUANTITATIVE POLYMERASE CHAIN REACTION WAS PERFORMED TO EXAMINE THE MRNA LEVELS OF HDAC2 AND GABA(A) RECEPTOR SUBUNITS. RESULTS: VTA NEURONS FROM THE WITHDRAWAL GROUP EXHIBITED GABA HYPOSENSITIVITY. IN VIVO SAHA TREATMENT 2 HOURS BEFORE SACRIFICE NORMALIZED THE SENSITIVITY OF VTA NEURONS TO GABA. ETOH WITHDRAWAL WAS ASSOCIATED WITH INCREASED HDAC2 AND DECREASED ACH3K9 PROTEIN LEVELS; SAHA TREATMENT NORMALIZED ACH3K9 LEVELS. INTERESTINGLY, NO SIGNIFICANT CHANGE WAS OBSERVED IN THE MRNA LEVELS OF HDAC2. THE MRNA LEVELS, BUT NOT PROTEIN LEVELS, OF GABA(A) RECEPTOR ALPHA1 AND ALPHA5 SUBUNITS WERE INCREASED DURING WITHDRAWAL. CONCLUSIONS: WITHDRAWAL FROM CHRONIC ETOH EXPOSURE RESULTS IN A DECREASE IN GABA-MEDIATED INHIBITION, AND THIS GABA HYPOSENSITIVITY IS NORMALIZED BY IN VIVO SAHA TREATMENT. DISRUPTION OF SIGNALING IN THE VTA PRODUCED BY ALTERATION OF GABA NEUROTRANSMISSION COULD BE 1 NEUROADAPTIVE PHYSIOLOGICAL PROCESS LEADING TO CRAVING AND RELAPSE. THESE RESULTS SUGGEST THAT HDACI PHARMACOTHERAPY WITH AGENTS LIKE SAHA MIGHT BE AN EFFECTIVE TREATMENT FOR ALCOHOLISM. 2018 5 893 32 CHRONIC ETHANOL EXPOSURE AND WITHDRAWAL IMPAIR SYNAPTIC GABA(A) RECEPTOR-MEDIATED NEUROTRANSMISSION IN DEEP-LAYER PREFRONTAL CORTEX. BACKGROUND: THE PREFRONTAL CORTEX (PFC) ACTS AS AN INTEGRATIVE HUB FOR THE PROCESSING OF CORTICAL AND SUBCORTICAL INPUT INTO MEANINGFUL EFFERENT SIGNALING, PERMITTING COMPLEX ASSOCIATIVE BEHAVIORS. PFC DYSFUNCTION IS CONSISTENTLY OBSERVED WITH ETHANOL (ETOH) DEPENDENCE AND IS A CORE COMPONENT OF THE PATHOLOGY OF ALCOHOL USE DISORDERS IN CURRENT MODELS OF ADDICTION. WHILE INTRACORTICAL GAMMA-AMINOBUTRYRIC ACID (GABA)ERGIC NEUROTRANSMISSION IS UNDERSTOOD TO BE ESSENTIAL FOR MAINTAINING COORDINATED NETWORK ACTIVITY WITHIN THE CORTEX, RELATIVELY LITTLE IS KNOWN REGARDING FUNCTIONAL GABAERGIC ADAPTATIONS IN PFC DURING ETOH DEPENDENCE. METHODS: IN THE PRESENT STUDY, MALE AND FEMALE (> POSTNATAL DAY 60) SPRAGUE-DAWLEY RATS WERE ADMINISTERED ETOH (5.0 G/KG; INTRAGASTRIC GAVAGE) FOR 14 TO 15 CONSECUTIVE DAYS. TWENTY-FOUR HOURS AFTER THE FINAL ADMINISTRATION, ANIMALS WERE SACRIFICED AND BRAINS EXTRACTED FOR ELECTROPHYSIOLOGICAL RECORDINGS OF ISOLATED GABA(A) RECEPTOR-MEDIATED CURRENTS OR ANALYSIS OF GABA(A) RECEPTOR SUBUNIT PROTEIN EXPRESSION IN DEEP-LAYER PFC NEURONS. RESULTS: CHRONIC ETOH EXPOSURE SIGNIFICANTLY ATTENUATED ACTIVITY-DEPENDENT SPONTANEOUS GABA(A) RECEPTOR-MEDIATED INHIBITORY POSTSYNAPTIC CURRENT (IPSC) FREQUENCY WITH NO EFFECT ON AMPLITUDE. FURTHERMORE, ANALYSIS OF IPSC DECAY KINETICS REVEALED A SIGNIFICANT ENHANCEMENT OF IPSC DECAY TIME THAT WAS ASSOCIATED WITH DECREMENTS IN EXPRESSION OF THE ALPHA1 GABA(A) RECEPTOR SUBUNIT, INDICATIVE OF FURTHER IMPAIRED PHASIC INHIBITION. THESE PHENOMENA OCCURRED IRRESPECTIVE OF NEURON PROJECTION DESTINATION AND SEX. BASED ON PREVIOUS OBSERVATIONS BY OUR LABORATORY OF AN EPIGENETIC MECHANISM FOR ETOH-INDUCED CHANGES IN CORTICAL GABA(A) RECEPTOR SUBUNIT EXPRESSION, THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A WAS ADMINISTERED TO WATER- AND ETOH-EXPOSED ANIMALS, AND PREVENTED ETOH-INDUCED CHANGES IN SPONTANEOUS IPSC FREQUENCY, IPSC DECAY KINETICS, AND GABA(A) RECEPTOR SUBUNIT EXPRESSION. CONCLUSIONS: TAKEN TOGETHER, THESE RESULTS DEMONSTRATE THAT CHRONIC ETOH EXPOSURE IMPAIRS SYNAPTIC INHIBITORY NEUROTRANSMISSION IN DEEP-LAYER PYRAMIDAL NEURONS OF THE MEDIAL PFC IN BOTH MALE AND FEMALE RATS. THESE MALADAPTATIONS OCCUR IN NEURONS PROJECTING TO NUMEROUS REGIONS IMPLICATED IN THE SEQUELAE OF ETOH DEPENDENCE, OFFERING A MECHANISTIC LINK BETWEEN THE MANIFESTATION OF PFC DYSFUNCTION AND NEGATIVE AFFECTIVE STATES OBSERVED WITH EXTENDED CONSUMPTION. 2019 6 5142 23 POTENTIAL ROLE FOR HISTONE DEACETYLATION IN CHRONIC DIAZEPAM-INDUCED DOWNREGULATION OF ALPHA1-GABA(A) RECEPTOR SUBUNIT EXPRESSION. CORROBORATING EVIDENCE INDICATE THAT THE DOWNREGULATION OF GABA(A) RECEPTOR SUBUNIT EXPRESSION MAY UNDERLIE TOLERANCE TO THE ANTICONVULSANT AND ANXIOLYTIC ACTIONS OF BENZODIAZEPINE (BZ) LIGANDS THAT ACT AS FULL ALLOSTERIC MODULATORS (FAMS) OF GABA ACTIONS AT A VARIETY OF GABA(A) RECEPTOR SUBTYPES. WE AND OTHERS HAVE SHOWN THAT 10-14 DAYS TREATMENT WITH INCREASING DOSES OF DIAZEPAM (A FAM) RESULTED IN ANTICONVULSANT TOLERANCE AND DECREASED THE EXPRESSION OF THE ALPHA1 GABA(A) RECEPTOR SUBUNIT MRNA AND PROTEIN IN FRONTAL CORTEX. IN ADDITION, WE HAVE ALSO SHOWN THAT LONG-TERM TREATMENT WITH IMIDAZENIL, A PARTIAL ALLOSTERIC MODULATOR OF GABA ACTION AT SELECTIVE GABA(A) RECEPTOR SUBTYPES, FAIL TO CHANGE THE EXPRESSION OF THE ALPHA1 SUBUNIT MRNA OR INDUCE TOLERANCE TO ITS ANTICONVULSANT OR ANXIOLYTIC ACTION. HOWEVER, LITTLE IS KNOWN REGARDING THE POTENTIAL ROLE OF EPIGENETIC MECHANISMS ON LONG-TERM BZ-INDUCED DOWNREGULATION OF GABA(A) RECEPTOR SUBUNIT. THEREFORE, WE EXAMINED THE ROLE OF HISTONE ACETYLATION AND DNA METHYLATION MECHANISMS ON LONG-TERM DIAZEPAM-INDUCED DOWNREGULATION OF THE ALPHA1 SUBUNIT MRNA EXPRESSION IN RAT FRONTAL CORTEX. WE FOUND THAT 10 DAYS TREATMENT WITH INCREASING DOSES OF DIAZEPAM BUT NOT IMIDAZENIL DECREASED THE EXPRESSION OF THE ALPHA1 GABA(A) RECEPTOR SUBUNIT MRNA AND PROMOTER ACETYLATION IN FRONTAL CORTEX. IN ADDITION, WE ALSO FOUND THAT 10 DAYS TREATMENT WITH DIAZEPAM BUT NOT IMIDAZENIL INCREASED THE EXPRESSION OF HISTONE DEACETYLASE (HDAC) 1 AND 2 IN FRONTAL CORTEX. THUS, THE INCREASED EXPRESSION OF HDAC1 AND HDAC2 (CLASS 1 HDACS) AND CONSEQUENTLY INCREASED HISTONE DEACETYLATION MECHANISM OF THIS CLASS 1 HDACS, MAY UNDERLIE LONG-TERM DIAZEPAM-INDUCED DECREASED EXPRESSION OF THE ALPHA1 GABA(A) RECEPTOR SUBUNIT MRNA IN FRONTAL CORTEX. 2018 7 4945 18 PATERNAL PRECONCEPTION EVERY-OTHER-DAY ETHANOL DRINKING ALTERS BEHAVIOR AND ETHANOL CONSUMPTION IN OFFSPRING. ALCOHOL USE DISORDER IS A DEVASTATING DISEASE WITH A COMPLEX ETIOLOGY. RECENT PRECLINICAL STUDIES HAVE REVEALED THAT PATERNAL PRECONCEPTION CHRONIC INTERMITTENT ETHANOL (ETOH) EXPOSURE VIA VAPORIZED ETOH ALTERED DRINKING BEHAVIORS AND SENSITIVITY TO ETOH SELECTIVELY IN MALE OFFSPRING. IN THE CURRENT STUDY, WE USED A VOLUNTARY ORAL ROUTE OF PATERNAL PRECONCEPTION ETOH EXPOSURE, I.E., INTERMITTENT EVERY-OTHER-DAY TWO-BOTTLE CHOICE DRINKING, AND TESTED OFFSPRING FOR BEHAVIORAL ALTERATIONS. FIFTEEN ETOH DRINKING SIRES AND 10 CONTROL SIRES WERE MATED TO ETOH NAIVE FEMALES TO PRODUCE ETOH-SIRED AND CONTROL-SIRED OFFSPRING. THESE OFFSPRING WERE TESTED USING THE ELEVATED PLUS MAZE, OPEN FIELD, DRINKING IN THE DARK, AND UNLIMITED ACCESS TWO-BOTTLE CHOICE ASSAYS. WE FOUND THAT PATERNAL PRECONCEPTION EVERY-OTHER-DAY TWO-BOTTLE CHOICE DRINKING RESULTED IN REDUCED ETOH CONSUMPTION SELECTIVELY IN MALE OFFSPRING IN THE DRINKING IN THE DARK ASSAY COMPARED TO CONTROL-SIRED OFFSPRING. NO DIFFERENCES WERE DETECTED IN EITHER SEX IN THE UNLIMITED ACCESS TWO-BOTTLE CHOICE AND ELEVATED PLUS MAZE ASSAYS. OPEN FIELD ANALYSIS REVEALED COMPLEX CHANGES IN BASAL BEHAVIOR AND ETOH-INDUCED BEHAVIORS THAT WERE SEX SPECIFIC. WE CONCLUDED THAT PATERNAL PRECONCEPTION VOLUNTARY ETOH CONSUMPTION HAS PERSISTENT EFFECTS THAT IMPACT THE NEXT GENERATION. THIS STUDY ADDS TO A GROWING APPRECIATION THAT ONE'S BEHAVIORAL RESPONSE TO ETOH AND ETOH DRINKING BEHAVIOR ARE IMPACTED BY ETOH EXPOSURE OF THE PRIOR GENERATION. 2019 8 5443 32 REPEATED METHAMPHETAMINE AND MODAFINIL INDUCE DIFFERENTIAL COGNITIVE EFFECTS AND SPECIFIC HISTONE ACETYLATION AND DNA METHYLATION PROFILES IN THE MOUSE MEDIAL PREFRONTAL CORTEX. METHAMPHETAMINE (METH) AND MODAFINIL ARE PSYCHOSTIMULANTS WITH DIFFERENT LONG-TERM COGNITIVE PROFILES: METH IS ADDICTIVE AND LEADS TO COGNITIVE DECLINE, WHEREAS MODAFINIL HAS LITTLE ABUSE LIABILITY AND IS A COGNITIVE ENHANCER. INCREASING EVIDENCE IMPLICATES EPIGENETIC MECHANISMS OF GENE REGULATION BEHIND THE LASTING CHANGES THAT DRUGS OF ABUSE AND OTHER PSYCHOTROPIC COMPOUNDS INDUCE IN THE BRAIN, LIKE THE CONTROL OF GENE EXPRESSION BY HISTONES 3 AND 4 TAILS ACETYLATION (H3AC AND H4AC) AND DNA CYTOSINE METHYLATION (5-MC). MICE WERE TREATED WITH A SEVEN-DAY REPEATED METH, MODAFINIL OR VEHICLE PROTOCOL AND EVALUATED IN THE NOVEL OBJECT RECOGNITION (NOR) TEST OR SACRIFICED 4DAYS AFTER LAST INJECTION FOR MOLECULAR ASSAYS. WE EVALUATED TOTAL H3AC, H4AC AND 5-MC LEVELS IN THE MEDIAL PREFRONTAL CORTEX (MPFC), H3AC AND H4AC PROMOTOR ENRICHMENT (CHIP) AND MRNA EXPRESSION (RT-PCR) OF NEUROTRANSMITTER SYSTEMS INVOLVED IN AROUSAL, WAKEFULNESS AND COGNITIVE CONTROL, LIKE DOPAMINERGIC (DRD1 AND DRD2), ALPHA-ADRENERGIC (ADRA1A AND ADRA1B), OREXINERGIC (HCRTR1 AND HCRTR2), HISTAMINERGIC (HRH1 AND HRH3) AND GLUTAMATERGIC (AMPA GRIA1 AND NMDA GRIN1) RECEPTORS. REPEATED METH AND MODAFINIL TREATMENT ELICITED DIFFERENT COGNITIVE OUTCOMES IN THE NOR TEST, WHERE MODAFINIL-TREATED MICE PERFORMED AS CONTROLS AND METH-TREATED MICE SHOWED IMPAIRED RECOGNITION MEMORY. METH-TREATED MICE ALSO SHOWED I) DECREASED LEVELS OF TOTAL H3AC AND H4AC, AND INCREASED LEVELS OF 5-MC, II) DECREASED H3AC ENRICHMENT AT PROMOTERS OF DRD2, HCRTR1/2, HRH1 AND GRIN1, AND INCREASED H4AC ENRICHMENT AT DRD1, HRH1 AND GRIN1, III) INCREASED MRNA OF DRD1A, GRIN1 AND GRIA1. MODAFINIL-TREATED MICE SHARED NONE OF THESE EFFECTS AND SHOWED INCREASED H3AC ENRICHMENT AND MRNA EXPRESSION AT ADRA1B. MODAFINIL AND METH SHOWED SIMILAR EFFECTS LINKED TO DECREASED H3AC IN HRH3, INCREASED H4AC IN HCRTR1, AND DECREASED MRNA EXPRESSION OF HCRTR2. THE SPECIFIC METH-INDUCED EPIGENETIC AND TRANSCRIPTIONAL CHANGES DESCRIBED HERE MAY BE RELATED TO THE LONG-TERM COGNITIVE DECLINE EFFECTS OF THE DRUG AND ITS DETRIMENTAL EFFECTS ON MPFC FUNCTION. THE LACK OF SIMILAR EPIGENETIC EFFECTS OF CHRONIC MODAFINIL ADMINISTRATION SUPPORTS THIS NOTION. 2018 9 6095 30 THE EFFECTS OF SINGLE-DOSE INJECTIONS OF MODAFINIL AND METHAMPHETAMINE ON EPIGENETIC AND FUNCTIONAL MARKERS IN THE MOUSE MEDIAL PREFRONTAL CORTEX: POTENTIAL ROLE OF DOPAMINE RECEPTORS. METH USE CAUSES NEUROADAPTATIONS THAT NEGATIVELY IMPACT THE PREFRONTAL CORTEX (PFC) LEADING TO ADDICTION AND ASSOCIATED COGNITIVE DECLINE IN ANIMALS AND HUMANS. IN CONTRAST, MODAFINIL ENHANCES COGNITION BY INCREASING PFC FUNCTION. ACCUMULATED EVIDENCE INDICATES THAT PSYCHOSTIMULANT DRUGS, INCLUDING MODAFINIL AND METH, REGULATE GENE EXPRESSION VIA EPIGENETIC MODIFICATIONS. IN THIS STUDY, WE MEASURED THE EFFECTS OF SINGLE-DOSE INJECTIONS OF MODAFINIL AND METH ON THE PROTEIN LEVELS OF ACETYLATED HISTONE H3 (H3AC) AND H4AC, DEACETYLASES HDAC1 AND HDAC2, AND OF THE NMDA SUBUNIT GLUN1 IN THE MEDIAL PFC (MPFC) OF MICE EUTHANIZED 1 H AFTER DRUG ADMINISTRATION. TO TEST IF DOPAMINE (DA) RECEPTORS (DRS) PARTICIPATE IN THE BIOCHEMICAL EFFECTS OF THE TWO DRUGS, WE INJECTED THE D1RS ANTAGONIST, SCH23390, OR THE D2RS ANTAGONIST, RACLOPRIDE, 30 MIN BEFORE ADMINISTRATION OF METH AND MODAFINIL. WE EVALUATED EACH DRUG EFFECT ON GLUTAMATE SYNAPTIC TRANSMISSION IN D1R-EXPRESSING LAYER V PYRAMIDAL NEURONS. WE ALSO MEASURED THE ENRICHMENT OF H3AC AND H4AC AT THE PROMOTERS OF SEVERAL GENES INCLUDING DA, NE, OREXIN, HISTAMINE, AND GLUTAMATE RECEPTORS, AND THEIR MRNA EXPRESSION, SINCE THEY ARE RESPONSIVE TO CHRONIC MODAFINIL AND METH TREATMENT. ACUTE MODAFINIL AND METH INJECTIONS CAUSED SIMILAR EFFECTS ON TOTAL HISTONE ACETYLATION, INCREASING H3AC AND DECREASING H4AC, AND THEY ALSO INCREASED HDAC1, HDAC2 AND GLUN1 PROTEIN LEVELS IN THE MOUSE MPFC. IN ADDITION, THE EFFECTS OF THE DRUGS WERE PREVENTED BY PRE-TREATMENT WITH D1RS AND D2RS ANTAGONISTS. SPECIFICALLY, THE CHANGES IN H4AC, HDAC2, AND GLUN1 WERE RESPONSIVE TO SCH23390, WHEREAS THOSE OF H3AC AND GLUN1 WERE RESPONSIVE TO RACLOPRIDE. WHOLE-CELL PATCH CLAMP IN TRANSGENIC BAC-DRD1A-TDTOMATO MICE SHOWED THAT METH, BUT NOT MODAFINIL, INDUCED PAIRED-PULSE FACILITATION OF EPSCS, SUGGESTING REDUCED PRESYNAPTIC PROBABILITY OF GLUTAMATE RELEASE ONTO LAYER V PYRAMIDAL NEURONS. ANALYSIS OF HISTONE 3/4 ENRICHMENT AT SPECIFIC PROMOTERS REVEALED: I) DISTINCT EFFECTS OF THE DRUGS ON HISTONE 3 ACETYLATION, WITH MODAFINIL INCREASING H3AC AT DRD1 AND ADRA1B PROMOTERS, BUT METH INCREASING H3AC AT ADRA1A; II) DISTINCT EFFECTS ON HISTONE 4 ACETYLATION ENRICHMENT, WITH MODAFINIL INCREASING H4AC AT THE DRD2 PROMOTER AND DECREASING IT AT HRH1, BUT METH INCREASING H4AC AT DRD1; III) COMPARABLE EFFECTS OF BOTH PSYCHOSTIMULANTS, INCREASING H3AC AT DRD2, HCRTR1, AND HRH1 PROMOTERS, DECREASING H3AC AT HRH3, INCREASING H4AC AT HCRTR1, AND DECREASING H4AC AT HCRTR2, HRH3, AND GRIN1 PROMOTERS. INTERESTINGLY, ONLY METH ALTERED MRNA LEVELS OF GENES WITH ALTERED HISTONE ACETYLATION STATUS, INDUCING INCREASED EXPRESSION OF DRD1A, ADRA1A, HCRTR1, AND HRH1, AND DECREASING GRIN1. OUR STUDY SUGGESTS THAT ALTHOUGH ACUTE METH AND MODAFINIL CAN BOTH INCREASE DA NEUROTRANSMISSION IN THE MPFC, THERE ARE SIMILAR AND CONTRASTING EPIGENETIC AND TRANSCRIPTIONAL CONSEQUENCES THAT MAY ACCOUNT FOR THEIR DIVERGENT CLINICAL EFFECTS. 2019 10 6175 29 THE HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ALLEVIATES DEPRESSION-LIKE BEHAVIOR AND NORMALIZES EPIGENETIC CHANGES IN THE HIPPOCAMPUS DURING ETHANOL WITHDRAWAL. WITHDRAWAL FROM CHRONIC ALCOHOL DRINKING CAN CAUSE DEPRESSION, LEADING TO AN INABILITY TO FUNCTION IN DAILY LIFE AND AN INCREASED RISK FOR RELAPSE TO HARMFUL DRINKING. UNDERSTANDING THE CAUSES OF ALCOHOL WITHDRAWAL-RELATED DEPRESSION MAY LEAD TO NEW THERAPEUTIC TARGETS FOR TREATMENT. EPIGENETIC FACTORS HAVE RECENTLY EMERGED AS IMPORTANT CONTRIBUTORS TO BOTH DEPRESSION AND ALCOHOL USE DISORDER (AUD). SPECIFICALLY, ACETYLATION OF THE N-TERMINAL TAILS OF HISTONE PROTEINS THAT PACKAGE DNA INTO NUCLEOSOMES IS ALTERED IN STRESS-INDUCED MODELS OF DEPRESSION AND DURING ALCOHOL WITHDRAWAL. THE GOAL OF THIS STUDY WAS TO EXAMINE DEPRESSION-LIKE BEHAVIOR DURING ALCOHOL WITHDRAWAL AND ASSOCIATED CHANGES IN HISTONE ACETYLATION AND EXPRESSION OF HISTONE DEACETYLASE 2 (HDAC2) IN THE HIPPOCAMPUS, A BRAIN REGION CRITICAL FOR MOOD REGULATION AND DEPRESSION. MALE SPRAGUE-DAWLEY RATS WERE TREATED WITH THE LIEBER-DECARLI ETHANOL LIQUID DIET FOR 15 DAYS AND THEN UNDERWENT WITHDRAWAL. RATS WERE TREATED WITH THE HDAC INHIBITOR, SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), DURING WITHDRAWAL AND WERE TESTED FOR DEPRESSION-LIKE BEHAVIOR. IN A SEPARATE GROUP OF RATS, THE HIPPOCAMPUS WAS ANALYZED FOR MRNA AND PROTEIN EXPRESSION OF HDAC2 AND LEVELS OF HISTONE H3 LYSINE 9 ACETYLATION (H3K9AC) DURING CHRONIC ETHANOL EXPOSURE AND WITHDRAWAL. RATS UNDERGOING ETHANOL WITHDRAWAL EXHIBITED DEPRESSION-LIKE BEHAVIOR AND HAD INCREASED HDAC2 AND DECREASED H3K9AC LEVELS IN SPECIFIC STRUCTURES OF THE HIPPOCAMPUS. TREATMENT WITH SAHA DURING WITHDRAWAL AMELIORATED DEPRESSION-LIKE BEHAVIOR AND NORMALIZED CHANGES IN HIPPOCAMPAL HDAC2 AND H3K9AC LEVELS. THESE RESULTS DEMONSTRATE THAT ETHANOL WITHDRAWAL CAUSES AN ALTERED EPIGENETIC STATE IN THE HIPPOCAMPUS. TREATMENT WITH AN HDAC INHIBITOR CAN CORRECT THIS STATE AND ALLEVIATE DEPRESSION-LIKE SYMPTOMS DEVELOPED DURING WITHDRAWAL. TARGETING HISTONE ACETYLATION MAY BE A NOVEL STRATEGY TO REDUCE ETHANOL WITHDRAWAL-INDUCED DEPRESSION. 2019 11 2827 28 FLUOXETINE INCREASES HIPPOCAMPAL NEUROGENESIS AND INDUCES EPIGENETIC FACTORS BUT DOES NOT IMPROVE FUNCTIONAL RECOVERY AFTER TRAUMATIC BRAIN INJURY. THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FLUOXETINE INDUCES HIPPOCAMPAL NEUROGENESIS, STIMULATES MATURATION AND SYNAPTIC PLASTICITY OF ADULT HIPPOCAMPAL NEURONS, AND REDUCES MOTOR/SENSORY AND MEMORY IMPAIRMENTS IN SEVERAL CNS DISORDERS. IN THE SETTING OF TRAUMATIC BRAIN INJURY (TBI), ITS EFFECTS ON NEUROPLASTICITY AND FUNCTION HAVE YET TO BE THOROUGHLY INVESTIGATED. HERE WE EXAMINED THE EFFICACY OF FLUOXETINE AFTER A MODERATE TO SEVERE TBI, PRODUCED BY A CONTROLLED CORTICAL IMPACT. THREE DAYS AFTER TBI OR SHAM SURGERY, MICE WERE TREATED WITH FLUOXETINE (10 MG/KG/D) OR VEHICLE FOR 4 WEEKS. TO EVALUATE THE EFFECTS OF FLUOXETINE ON NEUROPLASTICITY, HIPPOCAMPAL NEUROGENESIS AND EPIGENETIC MODIFICATION WERE STUDIED. STEREOLOGIC ANALYSIS OF THE DENTATE GYRUS REVEALED A SIGNIFICANT INCREASE IN DOUBLECORTIN-POSITIVE CELLS IN BRAIN-INJURED ANIMALS TREATED WITH FLUOXETINE RELATIVE TO CONTROLS, A FINDING CONSISTENT WITH ENHANCED HIPPOCAMPAL NEUROGENESIS. EPIGENETIC MODIFICATIONS, INCLUDING AN INCREASE IN HISTONE 3 ACETYLATION AND INDUCTION OF METHYL-CPG-BINDING PROTEIN, A TRANSCRIPTION FACTOR INVOLVED IN DNA METHYLATION, WERE LIKEWISE SEEN BY IMMUNOHISTOCHEMISTRY AND QUANTITATIVE WESTERN IMMUNOBLOTS, RESPECTIVELY, IN BRAIN-INJURED ANIMALS TREATED WITH FLUOXETINE. TO DETERMINE IF FLUOXETINE IMPROVES NEUROLOGICAL OUTCOMES AFTER TBI, GAIT FUNCTION AND SPATIAL LEARNING AND MEMORY WERE ASSESSED BY THE CATWALK-ASSISTED GAIT TEST AND BARNES MAZE TEST, RESPECTIVELY. NO DIFFERENCES IN THESE PARAMETERS WERE SEEN BETWEEN FLUOXETINE- AND VEHICLE-TREATED ANIMALS. THUS WHILE FLUOXETINE ENHANCED NEUROPLASTICITY IN THE HIPPOCAMPUS AFTER TBI, ITS CHRONIC ADMINISTRATION DID NOT RESTORE LOCOMOTOR FUNCTION OR AMELIORATE MEMORY DEFICITS. 2011 12 69 23 A MEDIAL PREFRONTAL CORTEX-NUCLEUS ACUMENS CORTICOTROPIN-RELEASING FACTOR CIRCUITRY FOR NEUROPATHIC PAIN-INCREASED SUSCEPTIBILITY TO OPIOID REWARD. RECENT STUDIES HAVE SHOWN THAT PERSISTENT PAIN FACILITATES THE RESPONSE TO MORPHINE REWARD. HOWEVER, THE CIRCUIT MECHANISM UNDERLYING THIS PROCESS REMAINS AMBIGUOUS. IN THIS STUDY, USING CHRONIC CONSTRICTION INJURY (CCI) OF THE SCIATIC NERVE IN MICE, WE FOUND THAT PERSISTENT NEUROPATHIC PAIN REDUCED THE MINIMUM NUMBER OF MORPHINE CONDITIONING SESSIONS REQUIRED TO INDUCE CONDITIONED PLACE PREFERENCE (CPP) BEHAVIOR. THIS DOSE OF MORPHINE HAD NO EFFECT ON THE PAIN THRESHOLD. IN THE MEDIAL PREFRONTAL CORTEX (MPFC), WHICH IS INVOLVED IN BOTH PAIN AND EMOTION PROCESSING, CORTICOTROPIN-RELEASING FACTOR (CRF) EXPRESSING NEURONAL ACTIVITY WAS INCREASED IN CCI MICE. CHEMOGENETIC INHIBITION OF MPFC CRF NEURONS REVERSED CCI-INDUCED MORPHINE CPP FACILITATION. FURTHERMORE, THE NUCLEUS ACUMENS (NAC) RECEIVED MPFC CRF FUNCTIONAL PROJECTIONS THAT EXERTED EXCITATORY EFFECTS ON NAC NEURONS. OPTOGENETIC INHIBITION OF MPCF NEURONAL TERMINALS OR LOCAL INFUSION OF THE CRF RECEPTOR 1 (CRFR1) ANTAGONIST IN THE NAC RESTORED THE EFFECTS OF NEUROPATHIC PAIN ON MORPHINE-INDUCED CPP BEHAVIOR, BUT NOT IN NORMAL MICE. ON A MOLECULAR LEVEL, IN CCI MICE, CRFR1 PROTEIN EXPRESSION WAS INCREASED IN THE NAC BY A HISTONE DIMETHYLTRANSFERASE G9A-MEDIATED EPIGENETIC MECHANISM. LOCAL G9A KNOCKDOWN INCREASED THE EXPRESSION OF CRFR1 AND MIMICKED CCI-INDUCED HYPERSENSITIVITY TO ACQUIRING MORPHINE CPP. TAKEN TOGETHER, THESE FINDINGS DEMONSTRATE A PREVIOUSLY UNKNOWN AND SPECIFIC MPFC CRF ENGAGEMENT OF NAC NEURONAL CIRCUITS, THE SENSITIZATION OF WHICH FACILITATES BEHAVIORAL RESPONSES TO MORPHINE REWARD IN NEUROPATHIC PAIN STATES VIA CRFR1S. 2018 13 881 27 CHRONIC CLOZAPINE TREATMENT RESTRAINS VIA HDAC2 THE PERFORMANCE OF MGLU2 RECEPTOR AGONISM IN A RODENT MODEL OF ANTIPSYCHOTIC ACTIVITY. PRECLINICAL FINDINGS IN RODENT MODELS POINTED TOWARD ACTIVATION OF METABOTROPIC GLUTAMATE 2/3 (MGLU2/3) RECEPTORS AS A NEW PHARMACOLOGICAL APPROACH TO TREAT PSYCHOSIS. HOWEVER, MORE RECENT STUDIES FAILED TO SHOW CLINICAL EFFICACY OF MGLU2/3 RECEPTOR AGONISM IN SCHIZOPHRENIA PATIENTS. WE PREVIOUSLY PROPOSED THAT LONG-TERM ANTIPSYCHOTIC MEDICATION RESTRICTED THE THERAPEUTIC EFFECTS OF THESE GLUTAMATERGIC AGENTS. HOWEVER, LITTLE IS KNOWN ABOUT THE MOLECULAR MECHANISM UNDERLYING THE POTENTIAL REPERCUSSION OF PREVIOUS ANTIPSYCHOTIC EXPOSURE ON THE THERAPEUTIC PERFORMANCE OF MGLU2/3 RECEPTOR AGONISTS. HERE WE SHOW THAT THIS MALADAPTIVE EFFECT OF ANTIPSYCHOTIC TREATMENT IS MEDIATED MOSTLY VIA HISTONE DEACETYLASE 2 (HDAC2). CHRONIC TREATMENT WITH THE ANTIPSYCHOTIC CLOZAPINE LED TO A DECREASE IN MOUSE FRONTAL CORTEX MGLU2 MRNA, AN EFFECT THAT REQUIRED EXPRESSION OF BOTH HDAC2 AND THE SEROTONIN 5-HT(2A) RECEPTOR. THIS TRANSCRIPTIONAL ALTERATION OCCURRED IN ASSOCIATION WITH HDAC2-DEPENDENT REPRESSIVE HISTONE MODIFICATIONS AT THE MGLU2 PROMOTER. WE FOUND THAT CHRONIC CLOZAPINE TREATMENT DECREASED VIA HDAC2 THE CAPABILITIES OF THE MGLU2/3 RECEPTOR AGONIST LY379268 TO ACTIVATE G-PROTEINS IN THE FRONTAL CORTEX OF MICE. CHRONIC CLOZAPINE TREATMENT BLUNTED THE ANTIPSYCHOTIC-RELATED BEHAVIORAL EFFECTS OF LY379268, AN EFFECT THAT WAS NOT OBSERVED IN HDAC2 KNOCKOUT MICE. MORE IMPORTANTLY, CO-ADMINISTRATION OF THE CLASS I AND II HDAC INHIBITOR SAHA (VORINOSTAT) PRESERVED THE ANTIPSYCHOTIC PROFILE OF LY379268 AND FRONTAL CORTEX MGLU2/3 RECEPTOR DENSITY IN WILD-TYPE MICE. THESE FINDINGS RAISE CONCERNS ON THE DESIGN OF PREVIOUS CLINICAL STUDIES WITH MGLU2/3 AGONISTS, PROVIDING THE RATIONALE FOR THE DEVELOPMENT OF HDAC2 INHIBITORS AS A NEW EPIGENETIC-BASED APPROACH TO IMPROVE THE CURRENTLY LIMITED RESPONSE TO TREATMENT WITH GLUTAMATERGIC ANTIPSYCHOTICS. 2019 14 4848 28 OPIOID-INDUCED STRUCTURAL AND FUNCTIONAL PLASTICITY OF MEDIUM-SPINY NEURONS IN THE NUCLEUS ACCUMBENS. OPIOID USE DISORDER (OUD) IS A CHRONIC RELAPSING CLINICAL CONDITION WITH TREMENDOUS MORBIDITY AND MORTALITY THAT FREQUENTLY PERSISTS, DESPITE TREATMENT, DUE TO AN INDIVIDUAL'S UNDERLYING PSYCHOLOGICAL, NEUROBIOLOGICAL, AND GENETIC VULNERABILITIES. EVIDENCE SUGGESTS THAT THESE VULNERABILITIES MAY HAVE NEUROCHEMICAL, CELLULAR, AND MOLECULAR BASES. KEY NEUROPLASTIC EVENTS WITHIN THE MESOCORTICOLIMBIC SYSTEM THAT EMERGE THROUGH CHRONIC EXPOSURE TO OPIOIDS MAY HAVE A DETERMINATIVE INFLUENCE ON BEHAVIORAL SYMPTOMS ASSOCIATED WITH OUD. IN PARTICULAR, STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE DENDRITIC SPINES OF MEDIUM SPINY NEURONS (MSNS) WITHIN THE NUCLEUS ACCUMBENS (NAC) AND ITS DOPAMINERGIC PROJECTIONS FROM THE VENTRAL TEGMENTAL AREA (VTA) ARE BELIEVED TO FACILITATE THESE BEHAVIORAL SEQUELAE. ADDITIONALLY, GLUTAMATERGIC NEURONS FROM THE PREFRONTAL CORTEX, THE BASOLATERAL AMYGDALA, THE HIPPOCAMPUS, AND THE THALAMUS PROJECT TO THESE SAME MSNS, PROVIDING AN ENRICHED TARGET FOR SYNAPTIC PLASTICITY. HERE, WE REVIEW LITERATURE RELATED TO NEUROADAPTATIONS IN NAC MSNS FROM DOPAMINERGIC AND GLUTAMATERGIC PATHWAYS IN OUD. WE ALSO DESCRIBE NEW FINDINGS RELATED TO TRANSCRIPTIONAL, EPIGENETIC, AND MOLECULAR MECHANISMS IN MSN PLASTICITY IN THE DIFFERENT STAGES OF OUD. 2021 15 5657 25 SEX-DEPENDENT PRONOCICEPTIVE ROLE OF SPINAL ALPHA(5) -GABA(A) RECEPTOR AND ITS EPIGENETIC REGULATION IN NEUROPATHIC RODENTS. EXTRASYNAPTIC ALPHA(5) -SUBUNIT CONTAINING GABA(A) (ALPHA(5) -GABA(A) ) RECEPTORS PARTICIPATE IN CHRONIC PAIN. PREVIOUSLY, WE REPORTED A SEX DIFFERENCE IN THE ACTION OF ALPHA(5) -GABA(A) RECEPTORS IN DYSFUNCTIONAL PAIN. HOWEVER, THE UNDERLYING MECHANISMS REMAIN UNKNOWN. THE AIM OF THIS STUDY WAS TO EXAMINE THIS SEXUAL DIMORPHISM IN NEUROPATHIC RODENTS AND THE MECHANISMS INVOLVED. FEMALE AND MALE WISTAR RATS OR ICR MICE WERE SUBJECTED TO NERVE INJURY FOLLOWED BY ALPHA(5) -GABA(A) RECEPTOR INVERSE AGONIST INTRATHECAL ADMINISTRATION, L-655,708. THE DRUG PRODUCED AN ANTIALLODYNIC EFFECT IN NERVE-INJURED FEMALE RATS AND MICE, AND A LOWER EFFECT IN MALES. WE HYPOTHESIZED THAT CHANGES IN ALPHA(5) -GABA(A) RECEPTOR, PROBABLY INFLUENCED BY HORMONAL AND EPIGENETIC STATUS, MIGHT UNDERLIE THIS SEX DIFFERENCE. THUS, WE PERFORMED QPCR AND WESTERN BLOT. NERVE INJURY INCREASED ALPHA(5) -GABA(A) MRNA AND PROTEIN IN FEMALE DORSAL ROOT GANGLIA (DRG) AND DECREASED THEM IN DRG AND SPINAL CORD OF MALES. TO INVESTIGATE THE HORMONAL INFLUENCE OVER ALPHA(5) -GABA(A) RECEPTOR ACTIONS, WE PERFORMED NERVE INJURY TO OVARIECTOMIZED RATS AND RECONSTITUTED THEM WITH 17BETA-ESTRADIOL (E2). OVARIECTOMY ABROGATED L-655,708 ANTIALLODYNIC EFFECT AND E2 RESTORED IT. OVARIECTOMY DECREASED ALPHA(5) -GABA(A) RECEPTOR AND ESTROGEN RECEPTOR ALPHA PROTEIN IN DRG OF NEUROPATHIC FEMALE RATS, WHILE E2 ENHANCED THEM. SINCE DNA METHYLATION MIGHT CONTRIBUTE TO ALPHA(5) -GABA(A) RECEPTOR DOWN-REGULATION IN MALES, WE EXAMINED CPG ISLAND DNA METHYLATION OF ALPHA(5) -GABA(A) RECEPTOR CODING GENE THROUGH PYROSEQUENCING. NERVE INJURY INCREASED METHYLATION IN MALE, BUT NOT FEMALE RATS. PHARMACOLOGICAL INHIBITION OF DNA METHYLTRANSFERASES INCREASED ALPHA(5) -GABA(A) RECEPTOR AND ENABLED L-655,708 ANTINOCICEPTIVE EFFECT IN MALE RATS. THESE RESULTS SUGGEST THAT ALPHA(5) -GABA(A) RECEPTOR IS A SUITABLE TARGET TO TREAT CHRONIC PAIN IN FEMALES. 2021 16 2670 34 ETHANOL ACTIONS ON THE VENTRAL TEGMENTAL AREA: NOVEL POTENTIAL TARGETS ON REWARD PATHWAY NEURONS. THE VENTRAL TEGMENTAL AREA (VTA) EVALUATES SALIENCE OF ENVIRONMENTAL STIMULI AND PROVIDES DOPAMINERGIC INNERVATION TO MANY BRAIN AREAS AFFECTED BY ACUTE AND CHRONIC ETHANOL EXPOSURE. WHILE PRIMARILY ASSOCIATED WITH REWARDING AND REINFORCING STIMULI, RECENT EVIDENCE INDICATES A ROLE FOR THE VTA IN AVERSION AS WELL. ETHANOL ACTIONS IN THE VTA MAY TRIGGER NEUROADAPTATION RESULTING IN REDUCTION OF THE AVERSIVE RESPONSES TO ALCOHOL AND A RELATIVE INCREASE IN THE REWARDING RESPONSES. IN SEARCHING FOR EFFECTIVE PHARMACOTHERAPIES FOR THE TREATMENT OF ALCOHOL ABUSE AND ALCOHOLISM, RECOGNITION OF THIS IMBALANCE MAY REVEAL NOVEL STRATEGIES. IN ADDITION TO CONVENTIONAL RECEPTOR/ION CHANNEL PHARMACOTHERAPIES, EPIGENETIC FACTORS THAT CONTROL NEUROADAPTATION TO CHRONIC ETHANOL TREATMENT CAN BE TARGETED AS AN AVENUE FOR DEVELOPMENT OF THERAPEUTIC APPROACHES TO RESTORE THE BALANCE. FURTHERMORE, WHEN EXPLORING THERAPIES TO ADDRESS REWARD/AVERSION IMBALANCE IN THE ACTION OF ALCOHOL IN THE VTA, SEX DIFFERENCES HAVE TO BE TAKEN INTO ACCOUNT TO ENSURE EFFECTIVE TREATMENT FOR BOTH MEN AND WOMEN. THESE PRINCIPLES APPLY TO A VTA-CENTRIC APPROACH TO THERAPIES, BUT SHOULD HOLD TRUE WHEN THINKING ABOUT THE OVERALL APPROACH IN THE DEVELOPMENT OF NEUROACTIVE DRUGS TO TREAT ALCOHOL USE DISORDERS. ALTHOUGH THE FUNCTIONS OF THE VTA ITSELF ARE COMPLEX, IT IS A USEFUL MODEL SYSTEM TO EVALUATE THE REWARD/AVERSION IMBALANCE THAT OCCURS WITH ETHANOL EXPOSURE AND COULD BE USED TO PROVIDE NEW LEADS IN THE EFFORTS TO DEVELOP NOVEL DRUGS TO TREAT ALCOHOLISM. 2018 17 6207 24 THE INHIBITION OF HISTONE DEACETYLASES REDUCES THE REINSTATEMENT OF COCAINE-SEEKING BEHAVIOR IN RATS. DRUG ADDICTION IS A CHRONIC BRAIN DISEASE CHARACTERIZED BY A PERSISTENT RISK OF RELAPSE, EVEN AFTER A LONG PERIOD OF ABSTINENCE. A CURRENT HYPOTHESIS STATES THAT RELAPSE RESULTS FROM LASTING NEUROADAPTATIONS THAT ARE INDUCED IN RESPONSE TO REPEATED DRUG ADMINISTRATION. THE ADAPTATIONS REQUIRE GENE EXPRESSION, SOME OF WHICH BEING UNDER THE CONTROL OF STABLE EPIGENETIC REGULATIONS. WE HAVE PREVIOUSLY DEMONSTRATED THAT PRETREATMENT WITH HISTONE DEACETYLASE (HDAC) INHIBITORS REDUCES THE COCAINE REINFORCING PROPERTIES AS WELL AS THE MOTIVATION OF RATS FOR COCAINE. WE SHOW HERE THAT THE SAME HDAC INHIBITORS, TRICHOSTATIN A AND PHENYLBUTYRATE, SIGNIFICANTLY REDUCED THE COCAINE-SEEKING BEHAVIOR INDUCED BY THE COMBINATION OF A COCAINE INJECTION TOGETHER WITH THE EXPOSURE TO A LIGHT CUE PREVIOUSLY ASSOCIATED WITH COCAINE TAKING. REINSTATEMENT OF DRUG-SEEKING BEHAVIOR WAS CARRIED OUT AFTER A 3-WEEK WITHDRAWAL PERIOD, WHICH CAME AFTER TEN DAILY SESSIONS OF COCAINE INTRAVENOUS SELF-ADMINISTRATION. OUR RESULTS SUGGEST THAT PHARMACOLOGICAL TREATMENT AIMED AT MODULATING EPIGENETIC REGULATION, AND PARTICULARLY TREATMENT THAT WOULD INHIBIT HDAC ACTIVITY, COULD REDUCE THE RISK OF RELAPSE, A MAJOR DRAWBACK IN THE TREATMENT OF DRUG ADDICTION. 2011 18 4500 30 MORPHINE-WITHDRAWAL AVERSIVE MEMORIES AND THEIR EXTINCTION MODULATE H4K5 ACETYLATION AND BRD4 ACTIVATION IN THE RAT HIPPOCAMPUS AND BASOLATERAL AMYGDALA. CHROMATIN MODIFICATION IS A CRUCIAL MECHANISM IN SEVERAL IMPORTANT PHENOMENA IN THE BRAIN, INCLUDING DRUG ADDICTION. PERSISTENCE OF DRUG CRAVING AND RISK OF RELAPSE COULD BE ATTRIBUTED TO DRUG-INDUCED EPIGENETIC MECHANISMS THAT SEEM TO BE CANDIDATES EXPLAINING LONG-LASTING DRUG-INDUCED BEHAVIOUR AND MOLECULAR ALTERATIONS. HISTONE ACETYLATION HAS BEEN PROPOSED TO REGULATE DRUG-SEEKING BEHAVIOURS AND THE EXTINCTION OF REWARDING MEMORY OF DRUG TAKING. IN THIS WORK, WE STUDIED THE EPIGENETIC REGULATION DURING CONDITIONED PLACE AVERSION AND AFTER EXTINCTION OF AVERSIVE MEMORY OF OPIATE WITHDRAWAL. THROUGH IMMUNOFLUORESCENCE ASSAYS, WE ASSESSED SOME EPIGENETIC MARKS (H4K5AC AND P-BRD4) IN CRUCIAL AREAS RELATED TO MEMORY RETRIEVAL -BASOLATERAL AMYGDALA (BLA) AND HIPPOCAMPUS-. ADDITIONALLY, TO TEST THE DEGREE OF TRANSCRIPTIONAL ACTIVATION, WE EVALUATED THE IMMEDIATE EARLY GENES (IEGS) RESPONSE (ARC, BDNF, CREB, EGR-1, FOS AND NFKB) AND SMARCC1 (CHROMATIN REMODELER) THROUGH RT-QPCR IN THESE NUCLEI. OUR RESULTS SHOWED INCREASED P-BRD4 AND H4K5AC LEVELS DURING AVERSIVE MEMORY RETRIEVAL, SUGGESTING A MORE OPEN CHROMATIN STATE. HOWEVER, TRANSCRIPTIONAL ACTIVATION OF THESE IEGS WAS NOT FOUND, THEREFORE SUGGESTING THAT OTHER SECONDARY RESPONSE MAY ALREADY BE HAPPENING. ADDITIONALLY, SMARCC1 LEVELS WERE REDUCED DUE TO MORPHINE CHRONIC ADMINISTRATION IN BLA AND DENTATE GYRUS. THE ACTIVATION MARKERS RETURNED TO CONTROL LEVELS AFTER THE RETRIEVAL OF AVERSIVE MEMORIES, REVEALING A MORE REPRESSED CHROMATIN STATE. TAKEN TOGETHER, OUR RESULTS SHOW A MAJOR ROLE OF THE TANDEM H4K5AC/P-BRD4 DURING THE RETRIEVAL OF AVERSIVE MEMORIES. THESE RESULTS MIGHT BE USEFUL TO ELUCIDATE NEW MOLECULAR TARGETS TO IMPROVE AND DEVELOP PHARMACOLOGICAL TREATMENTS TO ADDRESS ADDICTION AND TO AVOID DRUG RELAPSE. 2023 19 6536 26 TRANSCRIPTIONAL REGULATION OF TYPE-2 METABOTROPIC GLUTAMATE RECEPTORS: AN EPIGENETIC PATH TO NOVEL TREATMENTS FOR CHRONIC PAIN. ACTIVATION OF METABOTROPIC GLUTAMATE 2 (MGLU2) RECEPTORS INHIBITS PAIN TRANSMISSION AT THE SYNAPSES BETWEEN PRIMARY AFFERENT FIBERS AND NEURONS IN THE DORSAL HORN OF THE SPINAL CORD. IN ADDITION, MGLU2 RECEPTORS ARE FOUND IN PERIPHERAL NOCICEPTORS, AND IN PAIN-REGULATORY CENTERS OF THE BRAIN STEM AND FOREBRAIN. MGLU2 RECEPTOR AGONISTS PRODUCE ANALGESIA IN MODELS OF INFLAMMATORY AND NEUROPATHIC PAIN, BUT THEIR USE IS LIMITED BY THE DEVELOPMENT OF TOLERANCE. A NEW THERAPEUTIC STRATEGY COULD BE BASED ON THE TRANSCRIPTIONAL REGULATION OF MGLU2 RECEPTORS VIA THE ACETYLATION-PROMOTED ACTIVATION OF THE P65/RELA TRANSCRIPTION FACTOR. "EPIGENETIC" DRUGS THAT INCREASE MGLU2 RECEPTOR EXPRESSION, INCLUDING L-ACETYLCARNITINE AND INHIBITORS OF HISTONE DEACETYLASES, HAVE A DIFFERENT ANALGESIC PROFILE WITH NO TOLERANCE TO THE THERAPEUTIC EFFECT AFTER REPEATED DOSING. 2010 20 3177 23 H3K9ME2 REGULATION OF BDNF EXPRESSION IN THE HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IS INVOLVED IN THE DEPRESSIVE-LIKE PHENOTYPE INDUCED BY MATERNAL SEPARATION IN MALE RATS. BACKGROUND: EARLY LIFE STRESS (ELS) INDUCES A DEPRESSIVE-LIKE PHENOTYPE AND INCREASES THE RISK OF DEPRESSION. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) HAS BEEN CONFIRMED TO BE INVOLVED IN THE PATHOPHYSIOLOGY OF DEPRESSION. HOWEVER, THE MECHANISM BY WHICH ELS ALTERS THE EPIGENETIC REGULATION OF BDNF AND CHANGES SUSCEPTIBILITY TO DEPRESSION HAS NOT BEEN FULLY CLARIFIED. METHODS: THE PRESENT STUDY USED MATERNAL SEPARATION (MS) AND CHRONIC UNPREDICTED MILD STRESS (CUMS) TO ESTABLISH AN MS ANIMAL MODEL AND A DEPRESSIVE ANIMAL MODEL. WE ASSESSED DEPRESSIVE-LIKE BEHAVIOURS, INCLUDING ANHEDONIA, LOCOMOTOR ACTIVITY, ANXIETY-LIKE BEHAVIOUR, AND SPATIAL MEMORY, USING THE SUCROSE PREFERENCE TEST, THE OPEN FIELD TEST, THE ELEVATED PLUS MAZE TEST, AND THE MORRIS WATER MAZE TEST. WE ALSO INVESTIGATED BDNF AND H3K9ME2 EXPRESSION IN THE HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX (MPFC) BY IMMUNOHISTOCHEMISTRY, WESTERN BLOTTING, AND QPCR ANALYSIS. ADDITIONALLY, WE USED UNC0642, A SMALL MOLECULE INHIBITOR OF HISTONE METHYLTRANSFERASE (G9A), AS AN INTERVENTION. RESULTS: THE RESULTS SHOWED THAT CUMS INDUCED DEPRESSIVE-LIKE BEHAVIOURS IN RATS AND RESULTED IN INCREASED H3K9ME2 EXPRESSION AND DECREASED BDNF EXPRESSION IN THE HIPPOCAMPUS AND MPFC. MORE IMPORTANTLY, ADULT MS RATS EXPERIENCING CUMS HAD MORE SEVERE DEPRESSIVE BEHAVIOURS, HAD HIGHER EXPRESSION OF H3K9ME2 IN THE HIPPOCAMPUS AND MPFC, AND HAD LOWER EXPRESSION OF BDNF IN THE HIPPOCAMPUS AND MPFC. IN ADDITION, ADMINISTRATION OF THE G9A INHIBITOR REVERSED MOST OF THE CHANGES. CONCLUSIONS: OUR STUDY SUGGESTS THAT ELS CHANGED BDNF AND H3K9ME2 EXPRESSION IN THE RAT BRAIN, RESULTING IN A DEPRESSIVE-LIKE PHENOTYPE. 2021